Get App

WhatsApp Channel

Tune in to know the latest updates on the health industry

ETHealth Newsletters

Explore and Subscribe to our Daily Newsletters

Follow Us

Get updates of events and latest news from ETHealth on LinkedIn.

Online pharmacy Zur Rose improves 2022 core loss target

Zur Rose's forecast adjusted core loss (EBITDA) of between 70 million and 75 million Swiss francs ($76.39 million and $81.84 million) in 2022, compared with its previous range of 75 million to 85 million francs.
  • Published On Jan 19, 2023 at 04:01 PM IST
Read by: 100 Industry Professionals
Reader Image Read by 100 Industry Professionals
New Delhi: Zur Rose expects a smaller full-year core loss than previously guided, the Swiss online drug retailer said on Thursday, citing a faster-than-planned advance in its break-even programme for 2023.

It forecast adjusted core loss (EBITDA) of between 70 million and 75 million Swiss francs ($76.39 million and $81.84 million) in 2022, compared with its previous range of 75 million to 85 million francs.

Zur Rose also said its external revenue was 1.84 billion francs in 2022, down 5.4% year-on-year but in line with its guidance.
  • Published On Jan 19, 2023 at 04:01 PM IST
Be the first one to comment.
Comment Now

COMMENTS

Comment Now Read Comment (1)

Join the community of 2M+ industry professionals

Subscribe to our newsletter to get latest insights & analysis.

Download ETHealthworld App

  • Get Realtime updates
  • Save your favourite articles
Scan to download App
image